Nanoform Finland (NANOFH.HE) Stock Analysis & AI Equity Report
Nanoform Finland (NANOFH.HE) overview
Nanoform Finland (NANOFH.HE) stock analysis and AI equity research. For the latest completed financial year, 2025, Nanoform Finland reported revenue of EUR 3.5m and operating profit of EUR -22.3m; the year-end share price was 1.17 EUR and market capitalisation was EUR 99.7m. Nanoform Finland is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Nanoform Finland's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-23. Data will be refreshed during report generation.
About Nanoform Finland
Nanoform Finland Oyj is a Finnish listed biotechnology company that provides nanoparticle engineering and formulation services to pharmaceutical manufacturers. Its proprietary CESS technology and GMP manufacturing capabilities are used to improve drug bioavailability, increase drug loading, and support alternative delivery routes for small-molecule and large-molecule therapeutics.
Generate the Nanoform Finland report
Nanoform Finland is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Nanoform Finland and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.